Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection

• Global incidence rate of this sexual transmitted disease is at 87 million infections per year

• OMV technology is a powerful tool to induce protective systemic and mucosal immunity

• Data published in the peer reviewed journal MSphere of the American Society of Microbiology

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 Bilthoven, The Netherlands, 30 November 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it enrolled the first participant  in a phase I first in-human clinical trial of Avacc…

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccinee Bilthoven, The Netherlands, 6 October 2022 –  CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI’s US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2…

Intravacc awarded US$14.6 Million NIH/NIAID contract to develop Intranasal Gonorrhea vaccine

Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine Bilthoven, The Netherlands, 5 October 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a contract with base and options that may total US$14.6 million from the US National Institute…

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company’s SARS-CoV-2 intranasal candidate vaccine. These results…

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced the publication of the 2021 annual report and the expansion of its management team, with…

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced the signing of an exclusive licensing agreement with Beijing Zhifei…

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur Bilthoven, the Netherlands, and Paris, France, 22 March 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced the publication of a GMP (Good Manufacturing Practices) manufacturing and…

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine Bilthoven, the Netherlands, 5 January 2022 – Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with Dutch Leiden University Medical Center (LUMC) to develop and evaluate a…